CYTOBANK, INC.

Biotech · Acquired

Cloud-based platform for analysis and storage of single-cell flow and mass cytometry data with integrated computational workflows and machine learning algorithms

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$3.5M
Federal grants
$2.2M
4 awards · 2015–2019
Rank in peer group#36 of 36
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$1.3M
5 awards · Health and Human S
Rank in Biotech#168 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $3.5M$154K$1M$750K$150K$614K$653K
20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $3.5M$1M$750K$614K$653K

Latest events

  • Federal contractHealth and Human S · Cytobank License$64K
  • Federal grantHealth and Human S · Phase II · Accelerating Multi-modal Biomarker Discovery in Translational Research with Cloud Data Integration$653K
  • Federal contractHealth and Human S · Cytobank Software License$42K
  • Federal grantHealth and Human S · Phase II · Accelerating Multi-modal Biomarker Discovery in Translational Research with Cloud Data Integration$614K
  • Federal contractHealth and Human S · Igf::ot::igf Cytobank License$15K
  • Federal grantHealth and Human S · Phase I · Powering single cell research in multi-center studies with Cytobank cloud data integration$150K
  • Federal grantHealth and Human S · Phase II · Web Software for Drug Targeting Signaling Networks in Primary Cell Subsets$750K
Show 2 earlier federal awards
  • Federal contractHealth and Human S · Igf::ot::igf Rd - A Cloud Computing Platform For Cytometry, SBIR Topic 59, Phase II$1M
  • Federal contractHealth and Human S · Biomedical (basic) SBIR Topic 59, Phase I, A Cloud Computing Platform For Cytometry$154K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 36 peers

Line = median

Biotech · Platform

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Schrodinger, Inc.Similar federal contract value in Biotech · $1.3M in contracts
  • OMICRON BIOCHEMICALS, INC.Similar federal contract value in Biotech · $1.3M in contracts
  • AM BIOTECHNOLOGIES, LLCSimilar federal contract value in Biotech · $1.3M in contracts
  • MIRIMUS, INC.Similar federal contract value in Biotech · $1.3M in contracts
  • CONSEGNA PHARMA INCSimilar federal contract value in Biotech · $1.3M in contracts
  • MYEXPOSOME INCSimilar federal contract value in Biotech · $1.3M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .